Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlos Gaona Reyes

Internal Medicine Ponce, PR Medical Doctor

NPI 1003902743 CMS profile 505857

1214 Ave Munoz Rivera, Recinto Universitario, Ponce, PR 00719

Open in the dashboard

General payments

$1,598

41 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlos Gaona Reyes of Ponce, PR is reported in the CMS Open Payments database as having received $1,598 across 41 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $114 1
2024 General $284 3
2023 General $107 2
2022 General $228 4
2021 General $117 5
2020 General $62 5
2019 General $687 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlos Gaona Reyes
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Carlos Gaona Reyes were reported at $114. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Carlos Gaona Reyes Internal Medicine median Middle half National median
2019 $687 $159 $48–$570 $163
2020 $62 $119 $33–$402 $114
2021 $117 $135 $37–$521 $132
2022 $228 $141 $42–$496 $149
2023 $107 $149 $45–$519 $160
2024 $284 $154 $47–$537 $164
2025 $114 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $411 9 payments
  2. Boston Scientific Corporation $293 3 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $253 20 payments
  4. AstraZeneca Pharmaceuticals LP $228 3 payments
  5. Intuitive Surgical, Inc. $137 1 payment
  6. Dexcom, Inc. $114 1 payment
  7. Medtronic, Inc. $61 1 payment
  8. E.R. Squibb & Sons, L.L.C. $58 1 payment
  9. PBG Puerto Rico LLC $28 1 payment
  10. Covidien LP $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,598 41 payments
Products named General payments · program years 2019–2025
  1. XARELTO $411 9 payments
  2. LifeVest $253 20 payments
  3. FARXIGA $228 3 payments
  4. WATCHMAN FLX $223 2 payments
  5. Da Vinci Surgical System $137 1 payment
  6. Dexcom G6 Transmitter $114 1 payment
  7. WATCHMAN $70 1 payment
  8. SYMPLICITY G3 $61 1 payment
  9. ELIQUIS Cardiovascular $58 1 payment
  10. ELIQUIS Cardiovascular;Metabolic Disease $28 1 payment
  11. Other $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

3,175

Median for Internal Medicine: 777

Drug cost

$172,296

Median for Internal Medicine: $73,373

Branded share of claims

16.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 37 $37,758
Eliquis Apixaban Brand 28 $26,471
Janumet Sitagliptin Phos/Metformin Hcl Brand 18 $15,072
Jardiance Empagliflozin Brand 15 $14,061
Xarelto Rivaroxaban Brand 17 $13,004
Synthroid Levothyroxine Sodium Brand 100 $10,836
Brilinta Ticagrelor Brand 14 $8,767
Lantus Insulin Glargine,hum.Rec.Anlog Brand 47 $4,852
Atorvastatin Calcium Generic 237 $2,849
Famotidine Generic 265 $2,599

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

41 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record